Filing Details
- Accession Number:
- 0001437749-14-017696
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-09-30 21:25:28
- Reporting Period:
- 2014-09-23
- Filing Date:
- 2014-09-30
- Accepted Time:
- 2014-09-30 21:25:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
879682 | Viveve Medical Inc. | PLCSD | Electromedical & Electrotherapeutic Apparatus (3845) | 043153858 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1555775 | Brigitte Smith | C/O Gbs Venture Partners Level 5, 71 Collins Street Melbourne C3 VIC 3000 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-09-23 | 947,872 | $0.53 | 3,598,807 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2014-09-23 | 192,262 | $0.53 | 3,791,069 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Direct |
Footnotes
- Directly beneficially owned by GBS BioVentures III.
- GBS Venture Partners Limited is trustee for GBS BioVentures III and may be deemed to have sole voting and investment power over the shares beneficially owned by GBS BioVentures III. Brigitte Smith is the Managing Partner of GBS Venture Partners. Ms. Smith disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein
- Such amount includes (a) 192,262 shares directly beneficially owned by Ms. Smith (see footnote 5) and (b) 3,598,807 shares indirectly beneficially owned by Ms. Smith (see footnotes 1 and 2).
- Such amount includes shares issued upon conversion of a Viveve, Inc. convertible promissory note with an aggregate principal and interest amount of $85,716.55, at a conversion price of $0.53 per share.
- Such amount includes shares issued upon conversion of a Viveve, Inc. convertible promissory note with an aggregate principal and interest amount of $101,898.63, at a conversion price of $0.53 per share